Answers are grounded in this paper and cite their sources.
AGR can serve as a prognostic biomarker in managing HNC, and a low pretreatment AGR is strongly associated with adverse survival outcomes and advanced cancer status. Additional large-scale prospective trials must be conducted to assess the validity of our findings.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: